March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Q3 2025 Earnings Call Transcript November 4, 2025 Taysha Gene Therapies, Inc. misses on earnings expectations. Reported EPS ...
Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
Excerpts from recent editorials in the United States and abroad: ___ Nov. 9 The Washington Post says TrumpRx isn't the best way to lower prices In a landmark deal announced Thursday, President Donald ...
Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...
Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...
The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...
The presentation, to be delivered by Dr. Man-Fung Yuen, Chair Professor of Gastroenterology and Hepatology at The University of Hong Kong, features new data from nine patients across 22 doses in the ...
Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM ESTCompany ParticipantsKim Kelderman - CEO, President ...
CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation.
The KEYMAKER-U03 trial showed a triplet regimen of belzutifan, pembrolizumab, and lenvatinib significantly improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback